Myths vs. Facts: Getting Tecentriq (atezolizumab) Covered by Aetna (CVS Health) in Pennsylvania
Answer Box: Tecentriq (atezolizumab) requires prior authorization from Aetna (CVS Health) in Pennsylvania, with approval based on FDA-indicated use, PD-L1 testing results (≥1% for adjuvant NSCLC, ≥50% for first-line metastatic), and documentation of failed alternatives where required. If denied after internal appeal, Pennsylvania's Independent External Review program offers